Standard Biotools logo
LABStandard Biotools
Trade LAB now
Standard Biotools primary media

About Standard Biotools

Standard Biotools (NASDAQ:LAB) is a company engaged in the design, development, and commercialization of tools for the life sciences community. Its operations span across the development of innovative technologies and systems that enable genomic and cell biology research, aiming to contribute to breakthroughs in scientific understanding and medical research. Standard Biotools focuses on delivering high-quality solutions that meet the evolving needs of researchers and scientists in the biotechnological field. Their projects range from developing sophisticated instruments and consumables to providing comprehensive analytical software solutions. The company's objective is to accelerate scientific discovery by offering products that enhance the efficiency and effectiveness of laboratory research.

What is LAB known for?

Snapshot

Public US
Ownership
1999
Year founded
598
Employees
South San Francisco, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

Produtos e/ou serviços de Standard Biotools

  • Fluidigm - An integrated fluidic circuit technology designed for various genomic analysis applications, including genotyping, PCR, and next-generation sequencing.
  • C1 Single-Cell Auto Prep System - Enables automated preparation of single cells for genomic analysis, enhancing precision and efficiency in research.
  • Juno System - A microfluidic-based platform for genotyping and targeted DNA sequencing, offering high throughput and versatility in sample processing.
  • Biomark HD System - A high-throughput PCR system enabling sensitive and accurate gene expression analysis, genotyping and digital PCR.
  • Helios Mass Cytometer - Employs CyTOF technology for high-dimensional single-cell analysis, enabling detailed cell profiling in immunology and cancer research.
  • Access Array System - Facilitates high-throughput targeted resequencing, enriching multiple genomic targets in a single sequencing run for cost-effective variant detection.

equipe executiva do Standard Biotools

  • Dr. Michael Egholm Ph.D.President, CEO & Director
  • Mr. Hanjoon KimChief Financial Officer
  • Mr. Sean MackayChief Business Officer & Senior VP
  • Mr. Jonathan MickelsenVP & Chief Accounting Officer
  • John GrazianoVice President of Investor Relations
  • Ms. Elizabeth R. JensenChief Human Resources Officer
  • Mr. Mike MusgnugSenior VP & Chief Commercial Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.